US · Healthcare · Biotechnology
EPS came in at 0.92 against a street estimate of -0.17 — a beat of 641.2%.
Analysts rate PTC Therapeutics Inc a buy (12 buy, 1 hold, 1 sell out of 14) with an average price target of $101.07.
CONFIDENT PTC crushed Q2 with record $361M revenue, raised full-year guidance to $850–950M product sales. Sephience PKU drug accelerating globally with 1,647 patients; votoplam HD data strong, FDA discussion planned. Pipeline advancing with NLRP3, DHODH, and MSH3 splicing programs. Q2 2026 U.S. remains core; international accelerating. ~20–30 markets targeted in 2026; additional expansion into 2027+. Germany P&R expected H2 2026 finalization. Analysts pressed on PKU market penetration (only ~10% of addressable population), switching dynamics (normalization at 120µmol/L in BH4 prior responders), and votoplam's FDA accelerated pathway rationale (24-month cUHDRS efficacy, target engagement). Management highlighted long runway, real-world quality-of-life data, and precedent from gene therapy approvals. 2026-07-30…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 16.73% |
| RTW INVESTMENTS, LLC | 9.28% |
| Jupiter Topco LLC | 8.67% |
| HHG PLC | 8.62% |
| Vanguard Portfolio Management, LLC | 5.90% |
| State Street Corp | 5.51% |
| Wellington Management Company LLP | 4.95% |
| Vanguard Capital Management, LLC | 4.48% |
| Document | Date |
|---|---|
| Reg FD disclosure · Q3 2026 PTC THERAPEUTICS, INC. – FORM 8-K SUMMARY As of September 21, 2026 --- BUSINESS & SEGMENT HIGHLIGHTS • PTC Therapeutics completed acquisition of ST | 2026-09-21 |
| Material agreement · Q3 2026 PTC THERAPEUTICS, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • PTC Therapeutics acquiring ST-920 asset from Sangamo Therapeutics for $111 million upfr | 2026-08-28 |
| Reg FD disclosure · Q3 2026 PTC THERAPEUTICS, INC. – FORM 8-K SUMMARY --- HEADLINE NUMBERS • Acquisition price: $111 million upfront plus up to $100 million in contingent mile | 2026-08-13 |
| Quarterly report · Q2 2026 PTC THERAPEUTICS, INC. – Q2 2026 SUMMARY FOR RETAIL INVESTORS --- HEADLINE NUMBERS • Cash and marketable securities combined: $2,229.1 million (Jun | 2026-07-30 |
| Results announced · Q3 2026 PTC THERAPEUTICS Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q2 2026 total revenue: $361 million (product revenue $239 million) • Q2 2026 net incom | 2026-07-30 |
| Material agreement · Q2 2026 PTC THERAPEUTICS, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Company completed private offering of $550,000,000 aggregate principal amount of 0.0% C | 2026-06-18 |
| Quarterly report · Q1 2026 PTC THERAPEUTICS, INC. – Q1 2026 SUMMARY HEADLINE NUMBERS • Cash and marketable securities: $2,127.5 million (down from $1,945.4 million at year-end | 2026-05-07 |
| Proxy statement · Q2 2026 PROXY STATEMENT SUMMARY: PTC THERAPEUTICS, INC. (PTCT) --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect four Class I directors to serve unti | 2026-04-20 |
Readable in the app.
| Announcement | Date |
|---|---|
| Completed acquisition; rolling BLA submission expected Q4 2026 PTC Therapeutics announced on September 21, 2026 that it completed an acquisition (specific target not detailed in this filing). The company is advancing a drug candidate called ST-920 towar | 2026-09-21 |
| Acquisition of ST-920 program for $111 million upfront plus contingent payments PTC Therapeutics announced it is acquiring a drug candidate called ST-920 for $111 million upfront, plus up to $100 million in additional payments if the drug receives FDA approval ($80 mill | 2026-08-13 |
| Financial guidance for fiscal year 2026 provided with forward-looking statements PTC Therapeutics filed an 8-K on January 12, 2026, primarily consisting of administrative disclosures rather than material business announcements. The filing indicates the company provided a | 2026-01-12 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for PTC Therapeutics Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.